Novartis Faces Third Clinical Trial Setback in a Week as Muscle Drug Fails
Novartis has encountered its third clinical trial failure in a week, as a muscle drug did not meet its primary endpoint in a late-stage study.
Breaking
- Media literacy week turns attention to checking sources in an AI-shaped news feed
- UN Day message renews call for cooperation as the Charter reaches 81 years
- Doha World Investment Forum programme puts AI, SMEs and climate finance on the agenda
- EU digital simplification mandate advances, but existing compliance duties remain
- EU Inc moves to Council negotiating stage: what startup founders should distinguish
- NASA and Virginia Energy link weather datasets to electricity planning